Literature DB >> 26002375

Des-acyl ghrelin attenuates pilocarpine-induced limbic seizures via the ghrelin receptor and not the orexin pathway.

Jeanelle Portelli1, Jessica Coppens2, Thomas Demuyser2, Ilse Smolders3.   

Abstract

Des-acyl ghrelin, widely accepted to work independently of the ghrelin receptor, is increasingly being implicated in a number of biological functions. The involvement of des-acyl ghrelin in epilepsy has only been recently reported. In this study, apart from unravelling the effect of des-acyl ghrelin on seizure thresholds and seizure severity in two models of pilocarpine-induced seizures, we mainly attempted to unravel its anticonvulsant mechanism of action. Since it was found that des-acyl ghrelin administration affected food intake via the orexin pathway, we first determined whether this pathway was responsible for des-acyl ghrelin's seizure-attenuating properties using the dual orexin receptor antagonist almorexant. We noted that, while des-acyl ghrelin showed dose-dependent anticonvulsant effects against focal pilocarpine-evoked seizures in rats, almorexant did not affect seizure severity and did not reverse des-acyl ghrelin's anticonvulsant effect. Subsequently, to investigate whether the ghrelin receptor was implicated in des-acyl ghrelin's anticonvulsant properties, we tested this peptide in ghrelin receptor deficient mice and wild type mice, all infused with pilocarpine intravenously. Unexpectedly, we found that des-acyl ghrelin significantly elevated seizure thresholds in C57Bl/6 and wild type mice but not in ghrelin receptor knock-out mice. Taken together, our results indicate the involvement of the ghrelin receptor in the anticonvulsant effects of des-acyl ghrelin on pilocarpine-induced seizures. We also show for the first time that dual antagonism of hippocampal orexin receptors does not affect seizure severity.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Almorexant; Des-acyl ghrelin; Hippocampus; Mice; Orexin; Pilocarpine; Rats; Seizure

Mesh:

Substances:

Year:  2015        PMID: 26002375     DOI: 10.1016/j.npep.2015.04.004

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  6 in total

1.  Ghrelin upregulates the phosphorylation of the GluN2B subunit of the NMDA receptor by activating GHSR1a and Fyn in the rat hippocampus.

Authors:  Liza Berrout; Masako Isokawa
Journal:  Brain Res       Date:  2017-10-06       Impact factor: 3.252

2.  Acylated but not des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease.

Authors:  Jacqueline A Bayliss; Moyra Lemus; Vanessa V Santos; Minh Deo; John D Elsworth; Zane B Andrews
Journal:  J Neurochem       Date:  2016-03-11       Impact factor: 5.372

Review 3.  Preclinical evidence of ghrelin as a therapeutic target in epilepsy.

Authors:  Tongtong Ge; Wei Yang; Jie Fan; Bingjin Li
Journal:  Oncotarget       Date:  2017-06-02

4.  Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor.

Authors:  Jessica Coppens; Eduard Bentea; Jacqueline A Bayliss; Thomas Demuyser; Laura Walrave; Giulia Albertini; Joeri Van Liefferinge; Lauren Deneyer; Najat Aourz; Ann Van Eeckhaut; Jeanelle Portelli; Zane B Andrews; Ann Massie; Dimitri De Bundel; Ilse Smolders
Journal:  Int J Mol Sci       Date:  2017-03-04       Impact factor: 5.923

5.  Potentiality of ghrelin as antioxidant and protective agent.

Authors:  Rachid Akki; Kawtar Raghay; Mohammed Errami
Journal:  Redox Rep       Date:  2021-12       Impact factor: 4.412

Review 6.  Targeting the Ghrelin Receptor as a Novel Therapeutic Option for Epilepsy.

Authors:  An Buckinx; Dimitri De Bundel; Ron Kooijman; Ilse Smolders
Journal:  Biomedicines       Date:  2021-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.